IMMUPHARMA PLC

Board/Management Information • Jan 6, 2026

National Storage Mechanism | Additional information

RNS Number : 7128N

Immupharma PLC

06 January 2026

RNS REACH |6 JANUARY 2026

ImmuPharma PLC

("ImmuPharma" or the "Company")

IMMUPHARMA AT JP MORGAN CONFERENCE & BIOTECH SHOWCASE™

12-14 January 2026 | San Francisco

ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, announces that Tim McCarthy, CEO, Dr Tim Franklin, COO, and Dr Sebastien Goudreau, CSO, will be attending both the JP Morgan Conference and the Biotech Showcase from 12-14 January 2026, in San Francisco, USA.

The JP Morgan conference and Biotech Showcase are annual premier partnering events, designed to provide biotechnology companies with the opportunity to present to and connect with global Biopharma companies and investors.

End

For further information please contact:

ImmuPharma PLC (www.immupharma.co.uk) Tim McCarthy, Chief Executive Officer Lisa Baderoon, Head of Investor Relations	+44 (0) 207 206 2650 + 44 (0) 7721 413496
SPARK Advisory Partners Limited (NOMAD) Neil Baldwin Stanford Capital Partners (Joint Broker) Patrick Claridge, Bob Pountney SI Capital (Joint Broker) Nick Emerson	+44 (0) 203 368 3550 +44 (0) 20 3650 3650 +44 (0) 1483 413500

Notes to Editors

About ImmuPharma PLC

ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives.

For additional information about ImmuPharma please visit www.immupharma.co.uk

ImmuPharma's LEI (Legal Entity Identifier) code : 213800VZKGHXC7VUS895.

About JP Morgan Healthcare Conference

The J.P. Morgan Healthcare Conference 2026 is the industry's premier investment symposium. It draws over 8,000 attendees including pharma/biotech executives, investors, startups, analysts, and policymakers for strategic discussions and dealmaking.

About Biotech Showcase

Biotech Showcase in San Francisco is an investor‑focused partnering conference held each January alongside JP Morgan Healthcare Conference week. It is designed mainly for private and micro‑ to mid‑cap biotech companies to meet global investors and pharma executives.

About Reach announcements

Reach is an investor communication service aimed at assisting listed and unlisted (including AIM quoted) companies to distribute media only / non-regulatory news releases such as marketing messages, corporate and product information into the public domain. An RNS Regulatory announcement is required to be notified under the AIM Rules for Companies.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NRAAKPBDOBKDFDK